Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1995 1
1997 1
2003 2
2005 3
2006 1
2008 1
2009 1
2011 2
2012 2
2013 1
2018 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Epoetin Alfa.
[No authors listed] [No authors listed] 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000431 Free Books & Documents. Review.
Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study.
Lissy M, Ode M, Roth K. Lissy M, et al. Drugs R D. 2011;11(1):61-75. doi: 10.2165/11588270-000000000-00000. Drugs R D. 2011. PMID: 21410296 Free PMC article. Clinical Trial.
In analyses across both study parts, Epogen was exploratorily compared with Erypo/Eprex. A dense-sampling 48-hour pharmacokinetic profile was recorded at steady state after 11 doses of 100 IU epoetin alfa per kg of bodyweight. ...Thus, bioequivalence and equivalent potency …
In analyses across both study parts, Epogen was exploratorily compared with Erypo/Eprex. A dense-sampling 48-hour pharmacokinetic pro …
Factors influencing the immunogenicity of therapeutic proteins.
Schellekens H. Schellekens H. Nephrol Dial Transplant. 2005 Jun;20 Suppl 6:vi3-9. doi: 10.1093/ndt/gfh1092. Nephrol Dial Transplant. 2005. PMID: 15958824 Review.
An upsurge in the incidence of antibody-mediated pure red cell aplasia (PRCA) among patients taking one particular formulation of recombinant human erythropoietin (epoetin-alpha, marketed as Eprex(R)/Erypo(R); Johnson & Johnson) in Europe caused widespread concern. ...
An upsurge in the incidence of antibody-mediated pure red cell aplasia (PRCA) among patients taking one particular formulation of recombinan …
Optimizing anaemia management with subcutaneous administration of epoetin.
Besarab A. Besarab A. Nephrol Dial Transplant. 2005 Jun;20 Suppl 6:vi10-5. doi: 10.1093/ndt/gfh1098. Nephrol Dial Transplant. 2005. PMID: 15958820 Review.
An upsurge in the incidence of pure red cell aplasia (PRCA) was linked to the epoetin-alpha product Eprex/Erypo in Europe, and an increase in PRCA cases of the same magnitude was not seen in patients taking other epoetin products s.c. ...
An upsurge in the incidence of pure red cell aplasia (PRCA) was linked to the epoetin-alpha product Eprex/Erypo in Europe, and an inc …
Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery.
Boven K, Knight J, Bader F, Rossert J, Eckardt KU, Casadevall N. Boven K, et al. Nephrol Dial Transplant. 2005 May;20 Suppl 3:iii33-40. doi: 10.1093/ndt/gfh1072. Nephrol Dial Transplant. 2005. PMID: 15824129
The upsurge of antibody-mediated PRCA was almost exclusively associated with chronic kidney disease patients who received subcutaneous epoetin therapy and the formulation of epoetin-alpha distributed outside the USA (EPREX/ERYPO). A systematic programme of technical, immun …
The upsurge of antibody-mediated PRCA was almost exclusively associated with chronic kidney disease patients who received subcutaneous epoet …
Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin.
Casadevall N. Casadevall N. Nephrol Dial Transplant. 2003 Nov;18 Suppl 8:viii37-41. doi: 10.1093/ndt/gfg1091. Nephrol Dial Transplant. 2003. PMID: 14608000 Review.
The vast majority of these patients had been treated with the Eprex/Erypo brand of epoetin alfa, but there were also some cases in which patients had been receiving epoetin beta (NeoRecormon). ...
The vast majority of these patients had been treated with the Eprex/Erypo brand of epoetin alfa, but there were also some cases in wh …
Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study.
Haag-Weber M, Eckardt KU, Hörl WH, Roger SD, Vetter A, Roth K. Haag-Weber M, et al. Clin Nephrol. 2012 Jan;77(1):8-17. doi: 10.5414/cn107304. Clin Nephrol. 2012. PMID: 22185963 Clinical Trial.
Eligible patients were randomized to 52 weeks of treatment with HX575 or Erypo/Eprex at a starting dose of 25 IU/kg body weight 3 times weekly or 75 IU/kg body weight once weekly during Weeks 1 - 5. ...RESULTS: HX575 was equivalent to Erypo/Eprex in terms of maintai …
Eligible patients were randomized to 52 weeks of treatment with HX575 or Erypo/Eprex at a starting dose of 25 IU/kg body weight 3 tim …
Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.
Aapro M, Krendyukov A, Schiestl M, Gascón P. Aapro M, et al. BioDrugs. 2018 Apr;32(2):137-138. doi: 10.1007/s40259-018-0268-3. BioDrugs. 2018. PMID: 29492906 Free PMC article.
Figure 1, HX575 column, 5th box down, which previously read "SC HX575 vs. Eprex()/Erypo() 417 patients with CKD-related anemia" as shown here....
Figure 1, HX575 column, 5th box down, which previously read "SC HX575 vs. Eprex()/Erypo() 417 patients with CKD-related anemia" as sh …
Pharmacokinetic and pharmacodynamic study of three products of epoetin alfa as single subcutaneous dose in healthy volunteers.
di Girolamo G, Keller GA, Beider L, González CD, González Bagnes MF, González E, Fornari MC, Diez RA. di Girolamo G, et al. Fundam Clin Pharmacol. 2023 Jun;37(3):651-662. doi: 10.1111/fcp.12869. Epub 2023 Feb 10. Fundam Clin Pharmacol. 2023. PMID: 36639980 Clinical Trial.
The primary objective was to compare the pharmacokinetic profile of different formulations of epoetin alfa after a single subcutaneous administration to healthy volunteers of 40 000 IU of Eprex/Erypo and Hemax PFS. This clinical trial was conceived following an open-label, …
The primary objective was to compare the pharmacokinetic profile of different formulations of epoetin alfa after a single subcutaneous admin …
19 results